FDA, pharmacovigilance, adaptive trial

News Briefs

April 04, 2007

By info@clinpage.com

Genelabs Technologies announces that it had reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial of Prestara for treatment of systemic lupus. Relsys International, a provider…